[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100311707":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":37,"centralContacts":41,"locations":51,"responsibleParty":67,"collaborators":11,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":11,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":11,"enrollmentInfo":80,"targetDuration":11,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":11,"overallStatus":54,"whyStopped":11,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University Medical Centre Ljubljana","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"MEM-7 days doxycycline","ACTIVE_COMPARATOR",null,[13],"Drug: Doxycycline 100 milligram Oral Tablet bid, 7 days",{"label":15,"type":10,"description":11,"interventionNames":16},"MEM-14 days doxycycline",[17],"Drug: Doxycycline 100 milligram Oral Tablet bid, 14 days",{"label":19,"type":20,"description":11,"interventionNames":21},"Controls","PLACEBO_COMPARATOR",[22],"Drug: Controls without a history of lyme disease.",[24,29,33],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","Doxycycline 100 milligram Oral Tablet bid, 7 days","Patients will receive doxycycline for 7 days.",[9],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"Doxycycline 100 milligram Oral Tablet bid, 14 days","Patients will receive doxycycline for 14 days.",[15],{"type":25,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"Controls without a history of lyme disease.","No intervention.",[19],[38],{"name":39,"affiliation":5,"role":40},"Daša Stupica, MD PhD","PRINCIPAL_INVESTIGATOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":11,"email":46},"Daša Stupica, MD, PhD","CONTACT","+386 31 689 324","dasa.stupica@kclj.si",{"name":48,"role":44,"phone":49,"phoneExt":11,"email":50},"Maša Velušček, MD","+386 1 522 21 10","masa.veluscek@kclj.si",[52],{"facility":53,"status":54,"city":55,"state":11,"zip":11,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"University Medical center Ljubljana","RECRUITING","Ljubljana","Slovenia","SI",{"type":59,"coordinates":60},"Point",[61,62],14.50513,46.05108,{"lat":62,"lon":61},[65,66],{"name":43,"role":44,"phone":45,"phoneExt":11,"email":46},{"name":48,"role":44,"phone":49,"phoneExt":11,"email":50},{"type":40,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Daša Stupica","Principal Investigator","100311707","duration-of-doxycycline-treatment-in-mem-patients-100311707",false,"NCT03337932","Duration of Doxycycline Treatment in MEM Patients","Duration of Doxycycline Treatment in Patients With Multiple Erythema Migrans (MEM). A Randomized Clinical Trial","Inclusion Criteria:\n\n• multiple erythema migrans\n\nExclusion Criteria:\n\n* pregnancy or lactation\n* immunocompromised\n* serious adverse event to doxycycline\n* taking antibiotic with antiborrelial activity within 10 days\n* extracutaneous manifestations of lyme borreliosis",true,"ALL","18 Years",{"count":81,"type":82},200,"ESTIMATED","INTERVENTIONAL",[85],"NA","The purpose of this study is to compare the efficacy of 7-day versus 14-day doxycycline treatment in patients with multiple erythema migrans.",[88],"Erythema Chronicum Migrans","2026-04-27",{"date":91,"type":92},"2026-04-29","ACTUAL",{"date":94,"type":92},"2018-05-01",{"date":96,"type":82},"2027-12-31",{"name":5,"class":6},1]